Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) — Medicare Part D spending
Astrazeneca/Pra · Rank #308 by total Part D spend · CMS data year 2023
Medicare Part D spent $140,028,972 on Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) in 2023, the #308 drug by total Part D spending out of 3,598 drugs. That worked out to about $25.57 per dosage unit, $324 per claim and $624 per beneficiary, across 432,530 claims for 224,344 beneficiaries. Average spending per dosage unit fell -7.2% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) spending at a glance (2023)
| Metric | Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) |
|---|---|
| Total Part D spending (2023) | $140,028,972 |
| Total spending (2022) | $140,966,845 |
| Year-over-year change in total spending | -0.7% |
| Average spending per dosage unit (2023) | $25.57 |
| Change in spend per dosage unit (YoY) | -7.2% |
| Avg annual change per dosage unit (2019-2023 CAGR) | -2.5% |
| Average spending per claim (2023) | $324 |
| Average spending per beneficiary (2023) | $624 |
| Total claims (2023) | 432,530 |
| Beneficiaries (2023) | 224,344 |
| Total dosage units (2023) | 5,469,744 |
| Manufacturer(s) | Astrazeneca/Pra |
| National rank by total spend (of 3,598 drugs) | #308 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $140,966,845 | $140,028,972 | -0.7% |
| Avg spend per dosage unit | $27.56 | $25.57 | -7.2% |
| Avg spend per claim | $339 | $324 | — |
| Avg spend per beneficiary | $669 | $624 | — |
| Total claims | 416,347 | 432,530 | — |
| Beneficiaries | 210,784 | 224,344 | — |
How Budesonide-Formoterol Fumarate compares with nearby drugs
Drugs with total Part D spending closest to Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) (this drug, #308) | $140,028,972 | $25.57 | -7.2% |
| Lumakras (Sotorasib) (#306) | $140,234,716 | $111.46 | +34.9% |
| Metoprolol Tartrate* (Metoprolol Tartrate) (#307) | $140,066,633 | $0.0749 | +5.4% |
| Avonex (Interferon Beta-1a) (#309) | $139,326,335 | $8,211.49 | +7.4% |
| Vyvanse (Lisdexamfetamine Dimesylate) (#310) | $138,990,768 | $13.04 | +5.8% |
| Piqray (Alpelisib) (#311) | $138,440,781 | $461.12 | +6.1% |
Frequently asked questions
How much does Medicare Part D spend on Budesonide-Formoterol Fumarate?
Medicare Part D spent $140,028,972 on Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) in 2023 (the latest CMS data year), across 432,530 claims for 224,344 beneficiaries. That ranks #308 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Budesonide-Formoterol Fumarate?
In 2023, the weighted average Medicare Part D spending per dosage unit for Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) was $25.57. Compared with 2022 it fell -7.2%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Budesonide-Formoterol Fumarate?
CMS attributes Budesonide-Formoterol Fumarate (Budesonide/Formoterol Fumarate) to Astrazeneca/Pra in the 2023 Part D spending file. Average spending per claim was $324 and per beneficiary $624.
Is the Budesonide-Formoterol Fumarate figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20